Systemic and topical antiviral treatment for CMV anterior uveitis
Official title: Systemic and Topical Antiviral Control of Cytomegalovirus Anterior uveitis: TreatmentOutcomes (STACCATO)
Funded at University of California, San Francisco · NIH-11517252 · Data updated 2026-11-12
This project tests how oral and eye-drop antiviral medicines can help prevent vision loss from CMV-related eye inflammation in people with anterior uveitis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | June 1, 2026 |
| Project end | January 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $16,460 |
| NIH project number | 3UG1EY036344-01A1S2 |
| Project ID | NIH-11517252 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with CMV-associated anterior uveitis, including those requiring evaluation for antiviral therapy, may be eligible.
✕Less likely to help
Patients without CMV anterior uveitis or those unable to tolerate antiviral therapy may not benefit.
What this research studies
Cytomegalovirus anterior uveitis can cause serious eye damage and even blindness. The study explores antiviral strategies, including oral valganciclovir and topical ganciclovir, and compares them to non-drug approaches to find the best way to control inflammation and protect vision. By enrolling patients with this condition, the trial aims to clarify which treatment provides the safest and most effective relief while monitoring side effects. The research team will use clinical assessments and lab monitoring to track response, safety, and recurrence over time. This work could guide physicians in choosing practical, effective options for patients facing CMV-associated eye disease.
Why it matters
Potential benefit: If successful, patients with CMV anterior uveitis may gain clearer vision and fewer flare-ups with safer, more effective treatment options.
How similar studies have gone: Previous work suggests antiviral strategies can help control CMV eye inflammation, but direct comparative trials are lacking and this study aims to fill that gap.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Gonzales, John Alexander — University of California, San Francisco
- Study coordinator: Gonzales, John Alexander
Related research
Other NIH-funded projects on the same topics.
-
Adalimumab Dose Adjustment for Pediatric Uveitis in JIA
A pediatric study will test whether lowering how often kids with juvenile idiopathic arthritis–related uveitis take adalimumab can keep inflammation controlled while reducing side effects and cost.
-
Changing adalimumab dosing for children with juvenile arthritis–related eye inflammation
This project tries to see if giving lower or less frequent doses of adalimumab can keep eye inflammation under control in children with juvenile idiopathic arthritis.
-
Systemic and topical antiviral treatment for CMV anterior uveitis (STACCATO)
A new NIH-supported effort will test how well oral and eye-applied antiviral medicines control CMV-related anterior uveitis in affected patients.
-
Systemic and topical antiviral treatment for CMV anterior uveitis in patients
A patient-friendly look at using antiviral medicines to treat CMV-related eye inflammation and protect vision.
-
Systemic and topical antiviral control of CMV anterior uveitis: TreatmentOutcomes
A patient-focused look at how CMV eye inflammation in adults could be treated with pills, eye drops, or other strategies to prevent vision loss.
-
AI tool to standardize how uveitis is measured
This project builds an AI platform to consistently measure signs of posterior uveitis in lab models so researchers can compare and improve treatments for people with uveitis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.